Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inviragen and the Duke-National University of Singapore Graduate Medical School (Duke-NUS) have signed a memorandum of understanding (MOU), under which both the parties have decided to advance research and development of vaccines for the treatment of infectious disease like dengue fever, hand, foot and mouth disease and chikungunya.
Subscribe to our email newsletter
Inviragen is a developer of vaccines to protect against infectious diseases worldwide.
The MOU calls for the formation of a management committee co-chaired by Casey and Dan Stinchcomb, CEO of Inviragen, who will oversee the organizations’ collaborative activities.
Inviragen chief operating officer Joseph Santangelo said the scientists in the Duke-NUS Emerging Infectious Diseases Program are conducting research into viral pathogenesis and host immunology, and are pioneering methods to improve detection of emerging viral infections.